Vismodegib in PAMAM-dendrimers for potential theragnosis in skin cancer

Vismodegib in PAMAM-dendrimers for potential theragnosis in skin cancer

Vismodegib (VDG) is an antineoplastic, a first-in-class Hedgehog signaling pathway inhibitor, indicated to treat locally advanced or metastatic basal cell carcinoma. Treatment with this drug was approved in 2012 by the US-FDA for oral administration (dose of 150 mg per day) in patients with a refusa...

Full description

Saved in:
Bibliographic Details
Main Authors: David E. Ybarra (Author), Maria Natalia Calienni (Author), Luis Felipe Barraza Ramirez (Author), E. Tais Aguayo Frias (Author), Cristian Lillo (Author), Silvia del Valle Alonso (Author), Jorge Montanari (Author), Fernando C. Alvira (Author)
Format: Book
Published: Elsevier, 2022-07-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available

Similar Items